Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

• Published in: The New England journal of medicine Vol. 389; no. 8; pp. 710 - 721
• Main Authors: Sacher, Adrian, LoRusso, Patricia, Patel, Manish R., Miller, Wilson H., Garralda, Elena, Forster, Martin D., Santoro, Armando, Falcon, Alejandro, Kim, Tae Won, Paz-Ares, Luis, Bowyer, Samantha, de Miguel, Maria, Han, Sae-Won, Krebs, Matthew G., Lee, Jong-Seok, Cheng, Michael L., Arbour, Kathryn, Massarelli, Erminia, Choi, Yoonha, Shi, Zhen, Mandlekar, Sandhya, Lin, Mark T., Royer-Joo, Stephanie, Chang, Julie, Dharia, Neekesh V., Schutzman, Jennifer L., Desai, Jayesh
• Format: Journal Article Web Resource
• Language: English
• Published: Boston Massachusetts Medical Society 24.08.2023; Massachussetts Medical Society
• Subjects: Administration, Oral; Adverse events; Antineoplastic Agents; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; Antitumor activity; Biopsy; Cancer; Cancer therapies; Carcinoma, Non-Small-Cell Lung; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/genetics; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms; Colorectal Neoplasms/drug therapy; Colorectal Neoplasms/genetics; Confidence intervals; Critical Care; Critical Care General; Enrollments; Enzyme Inhibitors; Enzyme Inhibitors/administration & dosage; Enzyme Inhibitors/adverse effects; Enzyme Inhibitors/therapeutic use; Gastroenterology; Gastrointestinal Tract Cancer; Gene frequency; General Medicine; Genetics; Hematology; Hematology/Oncology; Human health sciences; Humans; K-Ras protein; KRAS protein, human; Lung Cancer; Lung Neoplasms; Lung Neoplasms/drug therapy; Lung Neoplasms/genetics; Medicine (all); Metastases; Metastasis; Mutation; Nervous system; Non-small cell lung carcinoma; Oncologie; Oncology; Oral administration; Patients; Pharmacokinetics; Proteins; Proto-Oncogene Proteins p21(ras); Proto-Oncogene Proteins p21(ras)/genetics; Pulmonary; Pulmonary/Critical Care; Pulmonary/Critical Care General; Sciences de la santé humaine; Small cell lung carcinoma; Solid tumors; Treatments in Oncology; Tumors
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2303810

Among patients with cancers bearing the KRAS G12C mutation who received divarasib at a 400-mg dose, 56% with lung cancer, 36% with colorectal cancer, and 36% with other tumor types had a confirmed response.